Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
"Drawing inspiration from the heart of Kentucky, the city of Louisville, and our RiverBats roots, this bold new design ...
The polycythemia vera market over the next few years is expected to substantially change and experience growth, as it will be dominated by two already approved products, Incyte/Novartis' JAKAFI ...
Red Lobster customers will once again be able to eat lobster to their heart's content, with the return of Lobsterfest, known this year as "The Greatest Lobsterfest of All Time," or GLOAT for short.
And just to be clear, Merck is a company I like, which, I believe, has amazing fundamentals. You don't need me to make the bull case for Merck: 9 of the last 10 articles on Seeking Alpha have a ...
Investors have taken to punishing pharma companies that appear unable to gauge demand for their top products.
Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per ...
Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback